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Abstract
Ductal carcinoma in situ of the breast is a non-obligate precursor of invasive breast cancer, and at its lower risk endmight not need
treatment, a hypothesis tested in several currently running randomized clinical trials. This review describes the heterogeneity of
grading ductal carcinoma in situ (DCIS). First it considers differences between low and high grade DCIS, and then it looks at
several grading schemes and highlights how different these are, not only in the features considered for defining a given grade but
also in their wording of a given variable seen in the grade in question. Rather than being fully comprehensive, the review aims to
illustrate the inconsistencies. Reproducibility studies on grading mostly suggestive of moderate agreement on DCIS differenti-
ation are also illustrated. The need for a well structured, more uniform and widely accepted language for grading DCIS is urged to
avoid misunderstanding based misclassifications and improper treatment selection.
Keywords Breast cancer . Ductal carcinoma in situ . Grade
Introduction - Something Personal, to Begin
with…
The first author, among many other (about 50) participants,
was asked to classify ductal carcinoma in situ (DCIS) along
several features (10 Bscored^ variables) in a set of nearly 150
digital slides each representing a single case from a series of
353 DCIS with known outcome. This task was accepted vol-
untarily as the study framing this exercise has very ambitious
and complex aims, which include sorting out some troubles of
DCIS classification and possibly clarifying which cases could
safely avoid the relatively uniform treatment of a heteroge-
neous disease summarized under the same name of DCIS.
The study coordinated by Jelle Wesseling from the
Netherlands Cancer Institute also looks at the possibility
whether standard morphology is capable of sorting out, iden-
tifying these latter cases, which are likely to be overtreated
with a Bone size fits all^ approach. So motivation, daily prac-
tice expertise (and beyond), a friendly relation with the coor-
dinator of the study were all there to go ahead and score the
cases. But then, at the first case, looking at the variables to
score and the advice to follow everyone’s own routine made
this author uncertain. By the end of the few hours spent on
grading DCIS and classifying it otherwise, the sense of chaotic
set of rules or chaos from the lack of rules and the feeling of
being far away from perfectness resulted in frustration. This
feeling initiated the writing of this review, which tries to give
an impression on how far we are from a uniform approach to
DCIS.
DCIS as a Precursor of Invasive Carcinomas
Ductal carcinoma in situ (DCIS) is well accepted as a non-
obligate precursor of invasive breast carcinomas. As invasive
breast cancer is not a single disease, it is more than logical that
its precursor cannot be one disease either. Invasive carcinomas
are classified according to histological type, grade, biomarker
expression, stage … etc. Similarly, DCIS is also classified
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along several features: e.g. pattern, grade, necrosis and bio-
marker expression.
It is currently held that low grade (well differentiated, grade
1) invasive breast carcinomas derive from low grade DCIS,
whereas high grade DCIS is the precursor of high grade (poor-
ly differentiated, grade 3) invasive carcinomas [1], and this –
not surprisingly – suggests that LG DCIS and HG DCIS have
different prognoses. For invasive carcinomas, the Nottingham
grading scheme [2] has gained worldwide acceptance, and is
generally recommended in guidelines [3–6]. This distin-
guishes between 3 histological grades with worsening prog-
nosis. On the other hand, gene expression profiling studies
have suggested a two-tiered prognostic separation, which
lumps mostly histological grade 1 tumours and part of grade
2 tumours into a single group, the molecular (genomic) low
grade category, and leaves the rest of histological grade 2
tumours and most grade 3 tumours for the molecular
(genomic) high grade category [7]. This could mean that
histological grade 2 tumours would reflect only our in-
ability to classify these tumours as of better or worse
prognosis on the basis of haematoxylin and eosin (HE)
stained histological slides. Being a mixture of low and
high genomic grade tumours, histological grade 2 carci-
nomas, as a group, obviously have intermediate prognosis
between grade 1 and 3 tumours.
Similarly to invasive breast carcinoma, DCIS has also been
found to be classifiable into two molecular grades with a split
of intermediate histological grade DCIS cases into low and
high molecular grades [8, 9]. In keeping with the above no-
tion, while the low-grade pathway and high grade pathway
seem generally accepted [1], there has been no proposition
to state that intermediate grade DCIS gives ground to grade
2 invasive carcinomas, although this may be true in a number
of cases.
As DCIS, by definition, does not give rise to metastases, its
treatment could be local alone. By removing / abolishing a
precursor lesion, one can prevent the disease which develops
from it. On the other hand, as DCIS is a non-obligate precur-
sor, removing lesions that will not progress to invasive carci-
noma constitutes overtreatment. The low grade pathway men-
tioned before is not only associated with a better prognosis,
but also with a slower rate of progression [10] and recurrence
[11–13], and also a continuous rate of recurrence [9]. Some
DCIS never progress to invasive carcinoma. By now, clinical
studies have formulated the aim of proving that observation of
low risk / low grade DCIS can have identical outcomes than
(is not inferior to) surgical removal ± radiotherapy of these
lesions [14–16]. The low risk DCIS trials (LORIS – LOw
RISk dcis trial, LORD – LOw Risk Dcis trial and COMET -
Comparison of Operative to Monitoring and Endocrine
Therapy) have well stated inclusion (and exclusion) criteria
[17]. Basically, they recruit screen detected patients presenting
with microcalcification alone and diagnosed with either low
grade (LORD) or low grade and low end of intermediate grade
non-high grade (LORIS, COMET)DCIS on the basis of (large
gauge) needle biopsies providing generous sampling. These
patients are randomized between observation (i.e. active sur-
veillance) and conventional surgery with or without radiother-
apy with the possible addition of endocrine therapy in
COMET [14–18].
But what do we or others mean by different grades of
DCIS?
Grading DCIS – A Babelian Mixture
of Languages
DCIS is traditionally graded as low, intermediate and high
grade, and this is the recommendation made by the last edition
of the European Guidelines [3]. There are cases, which are
textbook examples of low grade (Fig. 1a) and high grade
(Fig. 1b) DCIS, and probably even unexperienced pathologist
would also reach a good concordance in classifying them ac-
cording to grade. On the other hand, there are cases which
give more pain for those trying to grade them. This must be
partially related to the lack of uniformity in the guidelines for
grading the disease. Figure 2 highlights the features consid-
ered while classifying DCIS into one of the grades according
to some guidelines in use, and it shows that these features are
not fully identical (The aim of Fig. 2 is to give a visual
impression; Supplementary Table 1 summarizes the wording
for the interested [3–5, 18–25]). Nuclear size criteria are in-
cluded in many of these schemes, but as Fig. 3 highlights it,
there is ground to interpret the cases differently [3–5, 18,
20–25].
A further source of confusion may stem from the terminol-
ogy used. One of the first multinational European contempo-
rary proposal for classification was the one by Holland et al.,
and this distinguished between well, intermediately and poor-
ly differentiated DCIS [19]. As grade reflects differentiation in
cancer, and invasive breast carcinomas of (histological) grade
1 are well differentiated, whereas those of (histological) grade
2 and 3 are moderately and poorly differentiated, respectively,
it is tempting to equate the differentiation terminology with
grade. But the generally accepted Nottingham grading system
used for invasive breast carcinomas is a combined histological
grade [2], in contrast to the nuclear grading system described
by Black, which originally features a confusing (reverted)
meaning of grades (grade 1 being the worst) [26]. The well-
moderately/intermediately-poorly differentiated terminology
for DCIS is based on cytonuclear and architectural differenti-
ation [19], and therefore does not merely reflect the nuclear
grade often used for grading DCIS. When one uses the term
grade with a meaning corresponding to a set of complex nu-
clear and structural criteria (Fig. 2), reproducibility may suffer
from the lack of weighting between these criteria: e.g. when
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the nucleus is not large enough to qualify for high grade, but
structural features are those often seen in poorly differentiated
DCIS, e.g. the lack of cellular orientation is conspicuous, there
are many mitoses, necrosis is present.
To add to this confusion, the low risk (for recurrence, for
invasive recurrence, for upgrading between needle biopsy and
surgical specimen, for death after progression) of low risk
DCIS is not only related to nuclear grade / differentiation,
but also to other features like size / extent, margin involvement
or proximity, age, proliferation. This has given rise to formu-
late prognostic indices, scores or multifactorial classifications
[9, 20, 27–29] and molecular approaches.
Reproducibility of Classifying DCIS
As assessed by statistical means, the previously introduced and
currently used recommendations for grading DCIS are far from
being perfectly reproducible among observers. Several studies
have looked at the consistency of grading or prognostically clas-
sifyingDCIS, and generally found that theseDCIS classifications
were moderately reproducible, while a few others suggested
worse or somewhat better agreement (Supplementary Table 2
and Fig. 4 representing it)[6, 19, 20, 30–39]. This degree of in-
terobserver variability is also reflected by a recent analysis of
nearly 5000 DCIS diagnosed during a period of 4 years in the
Fig. 1 Examples of obvious low
(a) and high (b) grade DCIS.
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Fig. 2 Features considered for grading DCIS according to different recommendations. ACN: Australian Cancer Network; IKN: Integraal
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Netherlands, and suggesting that the proportion of low grade
DCIS varied between 6 and 24% by department. This is not so
surprising as Fig. 4 reflects results gained with uniform classifi-
cation criteria, whereas a questionnaire based assessment in the
quoted Dutch study revealed a heterogeneity in the grading
schemes used [40].
Although the values reflecting interobserver reproducibili-
ty for DCIS grading (Fig. 4) are not (much) worse than for
many other features judged by microscopy (e.g. the
grade of invasive breast carcinoma; the reporting of
microinvasion in carcinoma in situ; the identification
of lymphovascular invasion), they suggest that studies
looking at the prognosis or prognostic markers of
DCIS cannot ignore this degree of variability, and steps
aiming at improving this are warranted.
As seenwith othermorphological features, a classification in a
two-tiered system is always more consistent than one in a three-
tiered system, simply by the fact that by chance identical catego-
rization is greater. This is also exemplified by the study of Van
Bockstal et al. [38], who found that reproducibility is improved
when 2 categories are used instead of 3, but also highlighted that
the distinction between high grade versus non-high grade was
better (median Cohen’s kappa value: 0.53) than the distinction
between lowgrade versus non-lowgrade (medianCohen’s kappa
value: 0.39) (Fig. 4). This may be a worthwhile approach to
improve reproducibility of the prognostic grouping of DCIS on
morphological grounds, although as stated in the first section, the
intermediate grade might reflect our less than perfect ability to
distinguish between the good (low genomic grade, low risk) and
the bad (high genomic grade, high risk).
Further Inconsistencies
Beside the determination of differentiation, i.e. grading, there are
other inconsistencies in recommendations concerning the classi-
fication of DCIS. For some reasons, the 1997 consensus confer-
ence recommendations have included a comedo pattern among
the traditionally recognized non-special types of DCIS, therefore
making 5 major pattern categories: comedo, solid, cribriform,
micropapillary, papillary [21]. Others recognize Bcomedo^ only
as a type of necrosis, which can occurwith the solid, but alsowith
other patterns of DCIS [4]. For some, necrosis worth to be men-
tioned is only the central comedo type necrosis [4, 20], and
Reference/Scheme
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Fig. 4 Different agreement levels reached in reproducibility studies on DCIS grade [6, 19, 20, 31–39]
References x1 x1.5 x2 x2.5 x3 Normal cells for comparative size
[20] RBC
RBC G1
[5, 21, 22, 23, 25 ] RBC/ductal epithelial cell nucleus G2
RBC/ductal epithelial cell nucleus G3
[3, 4] RBC/ductal epithelial cell nucleus
[24] No comparative size
LORIS inclusion [18]
Fig. 3 Comparative nuclear size described in some publications concerning the grading of DCIS. RBC: red blood cell / erythrocyte [3–5, 18, 20–25]
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punctate, focal necrosis needs no reporting, whereas the 1997
Philadelphia Consensus Conference recommendation, and na-
tional guidelines following these recommendations recognize
non-comedo type (punctate) necrosis, too, and recommend
reporting it separately [21, 23].
Concluding Remarks
The fact that DCIS classification is not uniform and harmonious
is well recognized, and the need to establish a uniform classifica-
tion system was formulated before. This is even more stressed,
when studies try to prove that low grade or non-high grade (low
risk) DCIS may not require anything else than careful follow-up.
It is imperative to delineate what people should mean by low
grade / low risk DCIS, in order to have a uniform interpretation
not only of specific cases, but also of study results. Thismay have
an impact on patient treatment or omission of treatment.
It might perhaps be wise to introduce a new, previously
unused and uncompromised terminology as well, as disciples
of former schools may understand the same term differently,
as suggested by our Figs. 2 and 3. It seems that some existing
national or regional guidelines use the same sources to be
followed for grading DCIS, but obviously there are differ-
ences even between European countries and within counties.
The running trials aiming at clarifying the outcome of low-risk
DCIS without treatment also use somewhat different inclusion
criteria [17].
There is a need to sort out the heterogeneity in terminology
and the development of a common language that would mean
the same thing to all those who communicate on it in order to
avoid misclassification and the ensuing possibility of mistreat-
ment simply arising from misunderstanding.
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